Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Last year
Pharma
FDA+

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Last year
Pharma
Marketing

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Last year
Pharma

Califf talks bol­ster­ing do­mes­tic drug man­u­fac­tur­ing, for­eign in­spec­tions at House hear­ing

Last year
Pharma
FDA+

His­to­gen files for bank­rupt­cy; Barinthus Bio shares Ph1b/2 da­ta for HPV treat­ment

Last year
News Briefing

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Last year
R&D
In Focus

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Last year
R&D

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Last year
Pharma

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Last year
Peer Review

Con­sumer trust in physi­cians and phar­ma is up, but low­er for em­ploy­ers and biotech

Last year
Pharma
Marketing

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

Last year
Pharma
Marketing

Vedan­ta lays off CMC staffers; Kin­cell buys Imu­gene fa­cil­i­ty for $6M

Last year
Manufacturing

Lu­mi­cell nabs FDA ap­proval for drug-de­vice breast can­cer de­tec­tion sys­tem

Last year
Pharma
FDA+

Cor­ner Ther­a­peu­tics to hy­per­ac­ti­vate ‘the brains of the im­mune sys­tem’ with $54M launch

Last year
Financing
Startups

Bruk­er to ac­quire trou­bled spa­tial bi­ol­o­gy com­pa­ny NanoS­tring for $392M

Last year
Deals

Bio­haven’s $230M of­fer­ing; Plus, three new PIPEs

Last year
News Briefing

J&J, Bris­tol My­ers race to am­pli­fy CAR-T man­u­fac­tur­ing to meet la­bel ex­pan­sion in mul­ti­ple myelo­ma

Last year
Cell/Gene Tx
Manufacturing

23and­Me's CEO files plan to take com­pa­ny pri­vate

Last year
Health Tech

Bris­tol My­ers pitch­es in to Pathios’ $25M Se­ries B for GPCR in­hibitor

Last year
Financing
R&D

ARCH-backed start­up Met­sera launch­es with $290M to take on obe­si­ty gi­ants

Last year
Financing

Cerev­el notch­es Phase 3 Parkin­son's win ahead of Ab­b­Vie trans­ac­tion clos­ing

Last year
R&D

Ex­clu­sive: An­ces­try cut 6% of work­force as ge­neal­o­gy gi­ant strug­gles with sub­scrip­tion rev­enue

Last year
People
Health Tech

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Last year
R&D
Pharma

Lil­ly, in­sulin users end $13.5M set­tle­ment plan fol­low­ing fed­er­al judge's de­ci­sion

Last year
Pharma
Law
First page Previous page 169170171172173174175 Next page Last page
A service from the Financial Times